Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sarilumab - Regeneron/Sanofi

Next Previous
Drug Profile

Sarilumab - Regeneron/Sanofi

Alternative Names: Anti-IL 6 receptor antibody; Anti-interleukin 6 receptor antibody; Kevzara; REGN-88; SAR-153191

Latest Information Update: 14 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Regeneron Pharmaceuticals; sanofi-aventis
  • Developer Asahi Kasei Pharma Corp; Regeneron Pharmaceuticals; Sanofi
  • Class Anti-inflammatories; Antirheumatics; Antivirals; Monoclonal antibodies
  • Mechanism of Action Interleukin 6 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Rheumatoid arthritis
  • Registered Juvenile rheumatoid arthritis; Polymyalgia rheumatica
  • Discontinued Ankylosing spondylitis; COVID 2019 infections; Giant cell arteritis; Uveitis

Most Recent Events

  • 31 Jan 2025 Registered for Juvenile rheumatoid arthritis (In adolescents, In children) in Iceland, Norway, European Union, Liechtenstein (SC)
  • 31 Dec 2024 Registered for Polymyalgia rheumatica (Treatment-experienced) in European Union, Liechtenstein, Norway, Iceland (SC)
  • 18 Dec 2024 Launched for Rheumatoid arthritis in Hong Kong (SC)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top